Xeris Biopharma (NASDAQ:XERS) Reaches New 1-Year High – Still a Buy?

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)’s stock price reached a new 52-week high during mid-day trading on Monday . The company traded as high as $5.97 and last traded at $5.88, with a volume of 1014781 shares changing hands. The stock had previously closed at $5.81.

Analyst Ratings Changes

XERS has been the topic of a number of research analyst reports. Jefferies Financial Group restated a “buy” rating and set a $6.00 price target (up from $4.00) on shares of Xeris Biopharma in a research report on Wednesday, January 29th. Piper Sandler reaffirmed a “neutral” rating and issued a $4.00 target price (up from $3.00) on shares of Xeris Biopharma in a research note on Friday, March 7th. Craig Hallum increased their price objective on Xeris Biopharma from $5.00 to $6.50 and gave the company a “buy” rating in a research report on Friday, March 7th. Leerink Partners upped their target price on shares of Xeris Biopharma from $5.00 to $6.00 and gave the company an “outperform” rating in a research report on Friday, March 7th. Finally, HC Wainwright restated a “buy” rating and issued a $8.00 price objective (up from $6.60) on shares of Xeris Biopharma in a report on Friday, March 7th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $5.92.

Xeris Biopharma Stock Up 2.4 %

The company’s fifty day simple moving average is $3.88 and its two-hundred day simple moving average is $3.41. The company has a market capitalization of $915.94 million, a price-to-earnings ratio of -13.22 and a beta of 2.32.

Insider Activity

In other news, insider Beth Hecht sold 40,000 shares of the company’s stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $5.43, for a total transaction of $217,200.00. Following the completion of the transaction, the insider now directly owns 1,353,510 shares of the company’s stock, valued at $7,349,559.30. This represents a 2.87 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.56% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Xeris Biopharma

Institutional investors have recently bought and sold shares of the company. NewEdge Advisors LLC acquired a new stake in shares of Xeris Biopharma in the fourth quarter valued at approximately $34,000. R Squared Ltd acquired a new stake in shares of Xeris Biopharma in the fourth quarter valued at about $42,000. Cibc World Markets Corp bought a new stake in Xeris Biopharma during the fourth quarter worth about $44,000. Raymond James Financial Inc. acquired a new position in Xeris Biopharma during the fourth quarter valued at approximately $45,000. Finally, Two Sigma Advisers LP bought a new position in Xeris Biopharma in the fourth quarter valued at approximately $47,000. Institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.